高危/中危前列腺癌近距离治疗随机II期试验:HDR与LDR单疗法初步分析
加拿大癌症试验组PR19随机II期试验比较LDR(I-125 144 Gy)与单次HDR(19 Gy×1+前列腺内推量)单疗法治疗低/中危前列腺癌。103例随机分组,中位随访53个月,4年PSA控制率LDR为78.4%、HDR为21.2%,单次HDR因劣效于2019年5月关闭。LDR疾病控制率高但前6个月泌尿刺激症状更重。
要点
- LDR 4年PSA控制率78.4%,单次HDR仅21.2%,HDR劣效提前关闭。
- 局部进展率LDR 2%、HDR 13.5%,HDR单次方案不可接受。
- LDR前6个月泌尿刺激和肠道症状更重,3级毒性LDR 6例、HDR 2例。
核心结论
- LDR近距离治疗在4年时前列腺癌疾病控制率高,但前6个月泌尿症状影响更差。
- 单次HDR(19 Gy×1+前列腺内推量)与不可接受的癌症控制率相关。
研究设计与样本
- 随机II期试验(加拿大癌症试验组PR19,NCT02960087),纳入低危和中危前列腺癌患者。
- 随机分为Arm 1 LDR I-125至144 Gy或Arm 2 HDR 19 Gy×1+前列腺内推量。
- 共103例随机:LDR 51例,HDR 52例;中位年龄65岁,中位随访53个月。
- Arm 2因劣效证据于2019年5月关闭,后续开放第三臂HDR 13.5 Gy×2。
主要发现
- 4年PSA控制率(PSA<0.4 ng/ml)LDR为78.4%,HDR为21.2%。
- 局部进展率LDR为2%,HDR为13.5%。
- 3级毒性LDR 6例,HDR 2例。
- LDR前6个月泌尿刺激和肠道症状更差。
- 76%患者Gleason 3+4,90% PSA<10,80%分期T1c。
关键数值与推荐
- 主要终点为48个月前列腺癌控制,定义为PSA<0.4 ng/ml。
- LDR方案:I-125至144 Gy;HDR方案:19 Gy×1+前列腺内推量。
- 毒性评估采用CTCAE v4.0,生活质量采用EPIC 26。
临床怎么用
- LDR单疗法可作为低/中危前列腺癌的有效选择,但需告知前6个月泌尿刺激症状加重。
- 单次HDR 19 Gy×1+推量方案因癌症控制率低,不应作为标准治疗。
局限性
- 为随机II期试验的初步两臂分析,样本量103例。
- HDR单次臂因劣效提前关闭,随访时间中位53个月。
- 第三臂HDR 13.5 Gy×2结果未在本次报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVES: Low Dose-Rate Brachytherapy (LDR) and High Dose-Rate Brachytherapy (HDR) are options for favorable risk prostate cancer. We hypothesized that HDR provides comparable disease control with less urinary toxicity. Primary objective was to determine prostate cancer control at 48 months, defined as a PSA < 0.4 ng/ml. MATERIALS/METHODS: Eligible patients had low and intermediate risk diseases. Randomization was to Arm 1 LDR with I-125 to 144 Gy, or Arm 2 HDR with 19 Gy x1 + intraprostatic boost. Follow-up included PSA, toxicity (CTCAE v 4.0), and Quality of Life (EPIC 26). Arm 2 was closed in May 2019 due to evidence of inferior outcomes, and a third arm (HDR 13.5 Gy x 2) was opened. We report outcomes of Arms 1 (LDR) and 2 (HDR single fraction) prior to study amendment. RESULTS: 103 patients were randomized: 51 to LDR (Arm 1) and 52 to HDR (Arm 2). Median age 65 years; 76 % had Gleason 3 + 4, 90 % PSA < 10, and 80 % stage T1c. Median follow-up 53 months. PSA control at 4 years was 78.4 % for LDR, and 21.2 % for HDR. Local progression rates: 2 % LDR, 13.5 % HDR. Grade 3 toxicity occurred in 6 patients for LDR and 2 patients Arm 2. Urinary irritative and bowel symptoms were worse in the first 6 months for LDR. CONCLUSIONS: LDR brachytherapy has high prostate cancer disease control rate at 4 years, although with worse impact on urinary symptoms in the first 6 months. Single fraction HDR was associated with unacceptable cancer control.
引用
- Morton G, Vigneault E, Barkati M, et al. A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087). Radiother Oncol. 2025. PMID: 40930276. doi:10.1016/j.radonc.2025.111124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。